Chapman Tripp advised bio-fuels innovator LanzaTech on its recent US$60m capital raising round which attracted new and existing investors including Mitsui, Siemens, Khosla Ventures, Warehouse founder Stephen Tindall's K1W1 fund, Qiming Venture Partners, and the Malaysian Life Sciences Capital Fund.
Chapman Tripp has acted exclusively in New Zealand for LanzaTech since 2011, providing New Zealand legal advice to the company and its US-led legal team on both commercial and regulatory issues, including the Overseas Investment Act.
Partner Nick Wells and senior solicitor Greer Fredricson advised on the latest capital raising, which is the second round that the Chapman Tripp team has worked on for LanzaTech.
Nick Wells said: “This was a great result for LanzaTech, particularly in a market where capital at this level is hard to come by. We are delighted to play a continuing role in their success story.
“Chapman Tripp has established a unique position facilitating venture capital raising for New Zealand biotech companies seeking capital offshore. Typically these deals are led from the US and based on Silicon Valley standard documents so our experience, combined with our local knowledge, means we are well placed to help New Zealand companies navigate the capital raising process.”
Chapman Tripp is advising on another Silicon Valley focused biotech capital raising which we hope to see announced soon.
Chapman Tripp has further strengthened its expertise in this area with the recent appointment of Diana Diamond as a senior legal adviser. Diana advises clients in the pharmaceutical, biotech, medical device and food industries on corporate, commercial and regulatory matters.